BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 17606725)

  • 1. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.
    Wacker B; Nagrani T; Weinberg J; Witt K; Clark G; Cagnoni PJ
    Clin Cancer Res; 2007 Jul; 13(13):3913-21. PubMed ID: 17606725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study.
    Van Cutsem E; Li CP; Nowara E; Aprile G; Moore M; Federowicz I; Van Laethem JL; Hsu C; Tham CK; Stemmer SM; Lipp R; Zeaiter A; Fittipaldo A; Csutor Z; Klughammer B; Meng X; Ciuleanu T
    Br J Cancer; 2014 Nov; 111(11):2067-75. PubMed ID: 25247318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
    Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.
    Pérol M; Chouaid C; Pérol D; Barlési F; Gervais R; Westeel V; Crequit J; Léna H; Vergnenègre A; Zalcman G; Monnet I; Le Caer H; Fournel P; Falchero L; Poudenx M; Vaylet F; Ségura-Ferlay C; Devouassoux-Shisheboran M; Taron M; Milleron B
    J Clin Oncol; 2012 Oct; 30(28):3516-24. PubMed ID: 22949150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).
    Aranda E; Manzano JL; Rivera F; Galán M; Valladares-Ayerbes M; Pericay C; Safont MJ; Mendez MJ; Irigoyen A; Arrivi A; Sastre J; Díaz-Rubio E
    Ann Oncol; 2012 Jul; 23(7):1919-25. PubMed ID: 22156621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.
    Wu YL; Zhou C; Liam CK; Wu G; Liu X; Zhong Z; Lu S; Cheng Y; Han B; Chen L; Huang C; Qin S; Zhu Y; Pan H; Liang H; Li E; Jiang G; How SH; Fernando MCL; Zhang Y; Xia F; Zuo Y
    Ann Oncol; 2015 Sep; 26(9):1883-1889. PubMed ID: 26105600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
    Wu YL; Lee JS; Thongprasert S; Yu CJ; Zhang L; Ladrera G; Srimuninnimit V; Sriuranpong V; Sandoval-Tan J; Zhu Y; Liao M; Zhou C; Pan H; Lee V; Chen YM; Sun Y; Margono B; Fuerte F; Chang GC; Seetalarom K; Wang J; Cheng A; Syahruddin E; Qian X; Ho J; Kurnianda J; Liu HE; Jin K; Truman M; Bara I; Mok T
    Lancet Oncol; 2013 Jul; 14(8):777-86. PubMed ID: 23782814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting.
    Stepanski EJ; Reyes C; Walker MS; Satram-Hoang S; Leon L; Wojtowicz-Praga S; Miller PJ; Houts AC; Schwartzberg LS
    Pancreas; 2013 Jan; 42(1):32-6. PubMed ID: 22699203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
    Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
    Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional multi-center study.
    Westphalen CB; Kukiolka T; Garlipp B; Hahn L; Fuchs M; Malfertheiner P; Reiser M; Kütting F; Heinemann V; Beringer A; Waldschmidt DT
    BMC Cancer; 2020 Feb; 20(1):155. PubMed ID: 32093649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
    Zhou C; Wu YL; Chen G; Feng J; Liu XQ; Wang C; Zhang S; Wang J; Zhou S; Ren S; Lu S; Zhang L; Hu C; Hu C; Luo Y; Chen L; Ye M; Huang J; Zhi X; Zhang Y; Xiu Q; Ma J; Zhang L; You C
    Lancet Oncol; 2011 Aug; 12(8):735-42. PubMed ID: 21783417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).
    Brahmer JR; Lee JW; Traynor AM; Hidalgo MM; Kolesar JM; Siegfried JM; Guaglianone PP; Patel JD; Keppen MD; Schiller JH
    Eur J Cancer; 2014 Jan; 50(2):302-8. PubMed ID: 24246704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors.
    Zaborowska-Szmit M; Kowalski DM; Piórek A; Krzakowski M; Szmit S
    Pharmacol Rep; 2016 Dec; 68(6):1140-1148. PubMed ID: 27588390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
    Perez-Soler R
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S7-14. PubMed ID: 17239291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.
    da Cunha Santos G; Dhani N; Tu D; Chin K; Ludkovski O; Kamel-Reid S; Squire J; Parulekar W; Moore MJ; Tsao MS
    Cancer; 2010 Dec; 116(24):5599-607. PubMed ID: 20824720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).
    Zhou C; Wu YL; Chen G; Feng J; Liu XQ; Wang C; Zhang S; Wang J; Zhou S; Ren S; Lu S; Zhang L; Hu C; Hu C; Luo Y; Chen L; Ye M; Huang J; Zhi X; Zhang Y; Xiu Q; Ma J; Zhang L; You C
    Ann Oncol; 2015 Sep; 26(9):1877-1883. PubMed ID: 26141208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
    Iwai T; Moriya Y; Shirane M; Fujimoto-Ouchi K; Mori K
    Oncol Rep; 2012 Apr; 27(4):923-8. PubMed ID: 22209766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
    Boeck S; Jung A; Laubender RP; Neumann J; Egg R; Goritschan C; Vehling-Kaiser U; Winkelmann C; Fischer von Weikersthal L; Clemens MR; Gauler TC; Märten A; Klein S; Kojouharoff G; Barner M; Geissler M; Greten TF; Mansmann U; Kirchner T; Heinemann V
    Br J Cancer; 2013 Feb; 108(2):469-76. PubMed ID: 23169292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.